Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Gadobutrol Magnevist-controlled Body Study

NCT01050829
completedphase_3

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

NCT00185276
completedphase_1

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

NCT00310596
completed

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
completed

Magnevist Post-marketing Surveillance in Japan

NCT01376739

Clinical Trials (5)

Showing 5 of 5 trials
NCT01050829Phase 3

Gadobutrol Magnevist-controlled Body Study

Completed
NCT00185276Phase 3

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Completed
NCT00310596Phase 1

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

Completed
NCT00744939

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Completed
NCT01376739

Magnevist Post-marketing Surveillance in Japan

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5